Bio Medica Laboratories
· SME · NSE
Price Band
₹132–139
Lot Size
1000 shares
Issue Size
₹52 Cr
Min. Investment
₹1,39,000
Grey Market Premium
Indicative, updates through the day
Estimated listing price: ₹139
Subscription Status
Subscription data will appear once bidding opens.
About Bio Medica Laboratories
Incorporated in August 2015, Bio Medica Laboratories specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the-counter (OTC) medications in liquid and dry-powder injectable forms.der injectables. These injectables are available in both single-dose and multi-dose formats, serving the needs of both human and veterinary healthcare. It offers comprehensive range of products, including generic drugs, branded pharmaceuticals, over the counter (OTC) products, and other medications. The company operates on a B2B model, focusing exclusively on contract manufacturing. It develop formulations for various companies in accordance with their specific requirements and product specifications. It is certified for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certificate issued by the Food & Drugs Administration, Madhya Pradesh. It has two manufacturing facilities in Indore, Madhya Pradesh.
Issue Objectives
- Repayment of loan
- Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises
- General Corporate Purposes
- Issue Expense
Reservation
| Category | Shares Offered | % |
|---|---|---|
| QIB | 36,000 | 1% |
| NII (HNI) | 17,55,000 | 48.98% |
| − bNII > ₹10L | 11,70,000 | 0% |
| − sNII < ₹10L | 5,85,000 | 0% |
| Retail | 17,92,000 | 50.01% |
| Market Maker | 1,89,000 | 0% |
- QIB1.0%
- NII (HNI)49.0%
- − bNII > ₹10L0.0%
- − sNII < ₹10L0.0%
- Retail50.0%
- Market Maker0.0%
Market Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 2000 | ₹2,78,000 |
| Individual investors (IND) (Max) | 2 | 2000 | ₹2,78,000 |
| S-HNI (Min) | 3 | 3000 | ₹4,17,000 |
| S-HNI (Max) | 7 | 7000 | ₹9,73,000 |
| B-HNI (Min) | 8 | 8000 | ₹11,12,000 |
Financials (₹ Cr)
Valuations
EPS (Pre IPO)
10.67
EPS (Post IPO)
10.33
ROE
54.41%
P/E (Pre IPO)
13.03
P/E (Post IPO)
13.45
Price / Book
Market Cap
₹174.79 Cr.
Peers Comparison
| Company | P/E | ROE | Revenue |
|---|---|---|---|
| Goldline Pharmaceutical Ltd. | 10.47 | ₹11.61 Cr | |
| Speciality Medicines Ltd. | 9.27 | ₹29.14 Cr | |
| Accretion Nutraveda Ltd. | 26.27 | ₹24.77 Cr | |
| KRM Ayurveda Ltd. | 17.32 | ₹77.49 Cr | |
| Curis Lifesciences Ltd. | 12.44 | ₹27.52 Cr | |
| Aptus Pharma Ltd. | 11.29 | ₹13.02 Cr |
Contact Details
Bio Medica Laboratories Ltd. Address
- +91 7314102751
- companysecretary@biomedica.co.in
- https://www.biomedica.co.in/
Registrar Contact Details
Skyline Financial Services Pvt. Ltd.
- +91 11 4045 0193
- ipo@skylinerta.com
- https://skylinerta.com
- D-153/A, 1st Floor, Okhla Industrial Area Phase-I, New Delhi – 110020
Frequently Asked Questions
Key Dates
- Open Date
- 21 May 2026
- Close Date
- 25 May 2026
- Listing Date
- 29 May 2026
Issue Details
- Registrar
- Skyline Financial
- Lead Manager(s)
- Exchange
- NSE